Abstract
Meningioma is the most common benign brain tumor of adults. For 50 years, neurosurgery was the standard of care and has provided the basis for our evidence for the regions at risk, behavior, and patterns of relapse for this tumor with a long but persistent natural history. As its role in treatment of grade I lesions continues to evolve, it is increasingly clear that radiotherapy plays an important part in durable local control and long-term patient outcomes. However, there is considerable variation in radiotherapeutic approach, particularly as pertains to defining the region at risk (i.e., GTV and CTV), technique (radiosurgery vs. conventional fractionation), and indications for and timing of treatment (i.e., up front or at recurrence). This chapter provides guidance to the radiotherapeutic approach of benign meningioma based on evidence from multidisciplinary sources, including recommendations for margins based on control by extent of resection and pathologic analysis of subclinical tumor extension after dural stripping, and on timing of intervention based on histologic behavior of recurrent tumor with and without radiotherapy up front.
Dedicated to mentor and friend Dr. Moody D. Wharam, the embodiment of Aequanimitas
Stephanie E. Weiss, MD
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Meningioma
- Low-grade meningioma
- Grade I meningioma
- Radiosurgery
- Radiotherapy
- IMRT
- Dural tail
- Long-term follow-up
- Late effects
- Symptomatic edema
2.1 General Principles of Simulation and Target Delineation (Tables 2.1 and 2.2, Fig. 2.2)
-
CT simulation in a thermoplast mask at zero angulation.
-
Diagnostic CT to evaluate bone invasion requiring inclusion in GTV.
-
Volumetric 3D reconstructed thin slice (1.5 mm optimal) MRI with T1 pre-gadolinium and fat-suppressed post-gadolinium, with 3D reconstruction for target delineation. T2 and FLAIR may assist evaluation of dural/calvarial involvement.
-
Enhancing lesion on T1 with contrast, bone invasion, and tumor-adjacent dura at risk are targets.
-
Fuse MR with CT. If postoperative case, fuse preoperative and postoperative imaging.
-
Incorporate reconstructed thin-sliced coronal and sagittal MR cuts to help identify and assure three-dimensional coverage of region at risk.
-
Distinguish dural attachment (tumor) from dural tail, which is predominantly hypervascular tissue that may or may not harbor tumor cells along with all tumor-adjacent dura [1].
-
If MRI is contraindicated, use thin slice CT (1.0 mm slices) with and without contrast.
-
3D conformal RT, IMRT/VMAT, SRS, and proton therapy may be considered.
-
If optic structures or the pituitary abut tumor and/or likely to be in meaningful dose gradient, recommend pretreatment neuro-ophthalmology and endocrine consult, respectively, to assess baseline function. Patient may be at risk for life-threatening adrenal insuffiency over time, along with other endocrinopathies.
-
Keep in mind dose-gradient and setup uncertainty when considering SRS in proximity to critical structures.
2.2 Clinical Pearls
-
Parasagittal/parasinus lesions are high risk (~25–45%) for post-radiosurgical symptomatic edema requiring medical intervention. Consider conventional fractionation rather than SRS for these lesions [2,3,4].
-
If patients require steroids >3–4 weeks, consider Pneumocystis jiroveci pneumonia prophylaxis.
-
Consider trial of celecoxib in lieu of/in aid of tapering steroid for patients not tolerating/requiring long-term dexamethasone if not otherwise contraindicated.
-
Consider the association of long-term local control with extent of surgical resection/dural stripping [5] when determining region “at risk” (CTV) in radiation treatment planning.
-
Low-grade meningioma has a propensity for late relapse. ~50% of patients with “low-risk” lesions die a cause-specific death with extended follow-up of 25 years [6].
-
Relapse is associated with subsequent aggressive behavior regardless of up-front treatment [6, 7].
-
Data with long-term (≥10 years) median follow-up for SRS is limited. Actuarial data for disease with a propensity for late relapse tends to underestimate recurrence rates.
-
1.
Dose Prescriptions
-
For conventional fractionation: 54 Gy in 30 fractions (1.8 Gy/day), may dose paint to limit normal critical tissue (such as chiasm) to 50.4 Gy.
-
For stereotactic radiosurgery (SRS): 12–14 Gy in a single fraction, respecting normal tissue tolerances.
-
2.3 Treatment Planning Techniques (Tables 2.3 and 2.4)
-
Conventional fractionation: 3D CRT, IMRT, VMAT, and protons may all be used with the goal of minimizing dose to brain/critical structures. Dose painting may be necessary (i.e., 54 Gy to most of CTV, limiting critical structure such as optic nerve to 50.4). Mindful of dose to the pituitary, brain stem, cord, cochlea, and cranial nerves, considering long-term survival of most patients. Tolerance of critical structures compromised from baseline if they have been previously injured by tumor encroachment and/or surgical manipulation.
-
SRS: Data is retrospective and/or median follow-up of <10 years. Actuarial data tends to under-estimate risk of relapse for disease entities with a propensity for late failure. Be wary of outcome curves past median follow-up. Risk for symptomatic edema after radiosurgery may be as high as 25–45% for parasinus/parasagittal lesions [2,3,4, 9].
Side effects. Please see Table 2.5.
References
Rogers L, Jensen R, Perry A (2005) Chasing your dural tail: factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas: in Regard to DiBiase et al. (Int J Radiat Oncol Biol Phys 2004;60:1515-1519). Radiat Oncol Biol 62(2):616–618; author reply 618–619. https://doi.org/10.1016/j.ijrobp.2005.02.026
Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R (2014) Stereotactic radiation therapy for benign meningioma: long-term outcome in 318 patients. Int J Radiat Oncol Biol Phys 89(3):569–575. https://doi.org/10.1016/j.ijrobp.2014.02.042
Patil CG, Hoang S, D John Borchers III, Sakamoto G, Soltys SG, Gibbs IC, Griffith R Harsh IV, Chang SD, Adler JR Jr (2008) Predictors of peritumoral edema after stereotactic radiosurgery of supratentorial meningiomas. Neurosurgery 63(3):435–442. https://doi.org/10.1227/01.NEU.0000325257.58684.92
Girvigian MR, Chen JCT, Rahimian J, Miller MJ, Tome M (2008) Comparison of early complications for patients with convexity and parasagittal meningiomas treated with either stereotactic radiosurgery or fractionated stereotactic radiotherapy. Neurosurgery 62(5 Suppl):A19–A27; discussion A27–28. https://doi.org/10.1227/01.neu.0000325933.34154.cb
Kinjo T, al-Mefty O, Kanaan I (1993) Grade zero removal of supratentorial convexity meningiomas. Neurosurgery 33(3):394–399; discussion 399
Pettersson-Segerlind J, Orrego A, Lönn S, Mathiesen T (2011) 1-s2.0-S1878875011005997-Main. Wneu 76(6):564–571. https://doi.org/10.1016/j.wneu.2011.05.015
Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB, Rhoton AL (1997) Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39(2):427–436
Borovich B, Doron Y (1986) Recurrence of intracranial meningiomas: the role played by regional multicentricity. J Neurosurg 64(1):58–63. https://doi.org/10.3171/jns.1986.64.1.0058
Lee CC, Trifiletti DM, Sahgal A, DeSalles A, Fariselli L, Hayashi M, Levivier M, Ma L, Álvarez RM, Paddick I, Regis J, Ryu S, Slotman B, Sheehan J (2018) Stereotactic radiosurgery for benign (World Health Organization Grade I) cavernous sinus meningiomas-International Stereotactic Radiosurgery Society (ISRS) practice guideline: a systematic review. Neurosurgery 83(6):1128–1142. https://doi.org/10.1093/neuros/nyy009
Kelly PJ, Mannarino EG, Lewis JH, Hacker FL (2011) Defining the target for radiation therapy of meningiomas following resection: a multidisciplinary study of inter-observer variability. Int J Radiat Oncol. https://doi.org/10.1016/j.ijrobp.2011.06.075
Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J (2010) Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 76(3 Suppl):S28–S35. https://doi.org/10.1016/j.ijrobp.2009.07.1753
Takeda A, Shigematsu N, Suzuki S, Fujii M, Kawata T, Kawaguchi O, Uno T, Takano H, Kubo A, Ito H (1999) Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity. Radiat Oncol Biol 44(3):599–605
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Radiat Oncol Biol 21(1):109–122
Batth SS, Sreeraman R, Dienes E, Beckett LA, Daly ME, Cui J, Mathai M, Purdy JA, Chen AM (2013) Clinical-dosimetric relationship between lacrimal gland dose and ocular toxicity after intensity-modulated radiotherapy for sinonasal tumours. Br J Radiol 86(1032):20130459–20130457. https://doi.org/10.1259/bjr.20130459
Bhandare N, Moiseenko V, Song WY, Morris CG, Bhatti MT, Mendenhall WM (2012) Severe dry eye syndrome after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 82(4):1501–1508. https://doi.org/10.1016/j.ijrobp.2011.05.026
Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, Mendenhall WM (2010) Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 76(3 Suppl):S50–S57. https://doi.org/10.1016/j.ijrobp.2009.04.096
Mayo C, Yorke E, Merchant TE (2010) Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S36–S41. https://doi.org/10.1016/j.ijrobp.2009.08.078
Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J (2010) Radiation dose-volume effects of optic nerves and chiasm. Radiat Oncol Biol 76:S28–S35. https://doi.org/10.1016/j.ijrobp.2009.07.1753
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Weiss, S.E. (2021). Benign Meningioma. In: Halasz, L.M., Lo, S.S., Chang, E.L., Sahgal, A. (eds) Intracranial and Spinal Radiotherapy . Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-64508-3_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-64508-3_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-64507-6
Online ISBN: 978-3-030-64508-3
eBook Packages: MedicineMedicine (R0)